Published in Aust Prescr on February 01, 2017
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int (2006) 7.02
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet (2013) 4.58
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol (2009) 2.71
Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA (2009) 2.44
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant (2008) 2.41
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int (2014) 2.41
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29
Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med (1991) 2.28
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl (2003) 2.04
Itchy skin--a clinical problem for haemodialysis patients. Nephrol Dial Transplant (2007) 2.03
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int (2012) 1.86
Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol (2013) 1.66
Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med (1989) 1.50
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol (2006) 1.31
The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol (2010) 1.21
Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol (2008) 1.18
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest (1989) 1.12
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev (2011) 1.05
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol (2009) 1.03
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant (2006) 1.03
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) (2011) 1.00
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant (2015) 0.96
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol (2009) 0.92
Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol (2013) 0.91
Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int (2015) 0.89
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant (2008) 0.88
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol (2011) 0.86
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis (2009) 0.85
Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol (2010) 0.85
The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol (2014) 0.83
Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit (1993) 0.82
Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol (1996) 0.81
Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract (2010) 0.80
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol (2007) 0.80
Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial (2014) 0.79
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol (2015) 0.78
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis (2016) 0.78
A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats. PLoS One (2014) 0.78
Effect of phosphate binders on supplemental iron absorption in healthy subjects. J Clin Pharmacol (2002) 0.78
Iron-based phosphate binders - a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol (2015) 0.78
Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients. Hemodial Int (2013) 0.77
Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) (1985) 0.77
Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm (2013) 0.77
Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephrol Dial Transplant (1991) 0.76
Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost. Nephrology (Carlton) (2011) 0.76
Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis (1989) 0.76
Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia. Blood Purif (2015) 0.76
Calcium-based phosphate binders and chronic kidney disease. Lancet (2014) 0.76